Product Images Avtozma

View Photos of Packaging, Labels & Appearance

Figure 1 - avtozma 01
Figure 2 - avtozma 02
Figure A - avtozma 03
Figure B - avtozma 04
Figure C - avtozma 05
Figure D - avtozma 06
Figure E - avtozma 07
Figure F - avtozma 08
Figure G - avtozma 09
Figure H - avtozma 10
Figure I - avtozma 11
Figure J - avtozma 12
Figure K - avtozma 13
Figure L - avtozma 14
Figure M - avtozma 15
Figure N - avtozma 16
Figure A - avtozma 17
Figure B - avtozma 18
Figure C - avtozma 19
Figure D - avtozma 20
Figure E - avtozma 21
Figure F - avtozma 22
Figure G - avtozma 23
Figure H - avtozma 24
Figure I - avtozma 25
Figure J - avtozma 26
Figure K - avtozma 27
Figure L - avtozma 28
Figure M - avtozma 29
Figure N - avtozma 30
Figure O - avtozma 31
Principal Display Panel - 80 mg/4 mL Vial Carton - avtozma 32
Principal Display Panel - 200 mg/10 mL Vial Carton - avtozma 33
Principal Display Panel - 400 mg/20 mL Vial Carton - avtozma 34
PRINCIPAL DISPLAY PANEL - 162 mg/0.9 mL Prefilled Syringe Carton - NDC 72606-045-01 - avtozma 35
PRINCIPAL DISPLAY PANEL - 162 mg/0.9 mL Prefilled Syringe Carton - NDC 72606-045-02 - avtozma 36
PRINCIPAL DISPLAY PANEL - 4 Prefilled Syringe Carton - NDC 72606-045-03 - avtozma 37
RINCIPAL DISPLAY PANEL - 12 Prefilled Syringe Carton - NDC 72606-045-03 - avtozma 38
PRINCIPAL DISPLAY PANEL - 162 mg/0.9 mL Autoinjector Carton - NDC 72606-045-04 - avtozma 39
PRINCIPAL DISPLAY PANEL - 162 mg/0.9 mL Autoinjectors Carton - NDC 72606-045-05 - avtozma 40
PRINCIPAL DISPLAY PANEL - 4 Autoinjectors Carton - NDC 72606-045-06 - avtozma 41
PRINCIPAL DISPLAY PANEL - 12 Autoinjectors Carton - NDC 72606-045-06 - avtozma 42

Product Label Images

The following 42 images provide visual information about the product associated with Avtozma NDC 72606-042 by Celltrion Usa, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - avtozma 01

Not available.*

Figure 2 - avtozma 02

Figure A - avtozma 03

This text appears to be a description of components or parts of a medical device or syringe. It includes elements such as a plunger rod, finger flange, medicine window, needle guard, and a cap. It seems to be an instruction or guide showing the arrangement or order of these parts before and after use.*

Figure B - avtozma 04

This text describes the contents of a carton which includes a prefilled syringe, cotton ball or gauze with an alcohol swab, an adhesive bandage, and an FDA-cleared sharps disposal container. It seems to be a medical or first aid kit.*

Figure C - avtozma 05

Figure D - avtozma 06

Figure E - avtozma 07

Figure F - avtozma 08

Figure G - avtozma 09

Figure H - avtozma 10

Figure I - avtozma 11

Figure J - avtozma 12

Figure K - avtozma 13

Figure L - avtozma 14

Figure M - avtozma 15

Figure N - avtozma 16

Figure A - avtozma 17

This text provides instructions for a medical device, likely a syringe or injection kit, with details on actions to be taken before and after use. It mentions the expiration date, a body date, an orange indicator, a window for injection, and the components like a blue needle cover and an orange needle cover. The mention of a locked needle inside also indicates safety features of the device.*

Figure B - avtozma 18

This text provides a description of the contents of a carton. It includes cotton balls, an auto-injector, gauze, alcohol swabs, adhesive bandages, and a Sharps disposal container. These items are likely part of a first aid or medical kit.*

Figure C - avtozma 19

Figure D - avtozma 20

Figure E - avtozma 21

Figure F - avtozma 22

Figure G - avtozma 23

Figure H - avtozma 24

This text outlines the different options for administering medication, including self-injection as well as the involvement of caregivers and healthcare providers (HCP). It emphasizes the roles of caregivers and HCP in the administration process.*

Figure I - avtozma 25

Figure J - avtozma 26

Figure K - avtozma 27

Figure L - avtozma 28

Figure M - avtozma 29

Figure N - avtozma 30

Figure O - avtozma 31

Principal Display Panel - 80 mg/4 mL Vial Carton - avtozma 32

The text provided is a detailed description of Avtozma, a medication with the active ingredient tocilizumab-anoh. It is an injection containing 80 mg per 4 mL (20 mg/mL) for intravenous infusion after dilution. The medication is in single-dose vials, and any unused portion should be discarded. The product should be stored refrigerated at 2-5°C and protected from light, without freezing or shaking. The dosage information should be obtained from prescribing information.*

Principal Display Panel - 200 mg/10 mL Vial Carton - avtozma 33

Principal Display Panel - 400 mg/20 mL Vial Carton - avtozma 34

This text provides information on a medication called Avtozma, specifically detailing the dosage, administration, and storage instructions for the injection. Avtozma contains tocilizumab-anoh and is intended for intravenous infusion after dilution. The medication is available in a 400 mg/20 mL strength, with a single-dose vial packaging. It emphasizes the importance of discarding any unused portion and mentions storage requirements. The text also includes pharmacode details and a reference to the product's identification numbers.*

PRINCIPAL DISPLAY PANEL - 162 mg/0.9 mL Prefilled Syringe Carton - NDC 72606-045-01 - avtozma 35

PRINCIPAL DISPLAY PANEL - 162 mg/0.9 mL Prefilled Syringe Carton - NDC 72606-045-02 - avtozma 36

This is information about the medication Avtozma containing tocilizumab-anoh in an injection form, with a dosage of 162 mg/0.9 mL for subcutaneous use only. The medication guide should be dispensed to each patient. The prefilled syringes come with a safety guard for ease of use.*

PRINCIPAL DISPLAY PANEL - 4 Prefilled Syringe Carton - NDC 72606-045-03 - avtozma 37

This text provides information about single-dose prefilled syringes with a safety guard for subcutaneous use only. The syringe contains a medication called Avtozma (tocilizumab-anoh) at a concentration of 162 mg/0.9 mL. It is advised to dispense the enclosed Medication Guide to each patient. The medication does not contain preservatives and is manufactured by CELLTRION. The text also includes details about the manufacturer's location and distribution in the USA.*

RINCIPAL DISPLAY PANEL - 12 Prefilled Syringe Carton - NDC 72606-045-03 - avtozma 38

Reonly Avtozma is a medication available in injection form with a concentration of 162 mg/0.9 mL intended for subcutaneous use only. The product comes in a multipack containing three cartons, with each carton containing four 0.9-mL single-dose prefilled syringes with a safety guard. Additionally, each multipack includes a Medication Guide, Prescribing Information, and Instructions for Use. The National Drug Code for this product is 72606-045-03.*

PRINCIPAL DISPLAY PANEL - 162 mg/0.9 mL Autoinjector Carton - NDC 72606-045-04 - avtozma 39

PRINCIPAL DISPLAY PANEL - 162 mg/0.9 mL Autoinjectors Carton - NDC 72606-045-05 - avtozma 40

The text describes a medication that comes in single-dose autoinjectors for subcutaneous use only. It includes ingredients such as risperidone, listine hydrochloride, and meticrine. The medication does not contain preservatives. The text also mentions a medication guide that should be dispensed to each patient. The medication is manufactured by Celltrion, and the text provides information on dosage and distribution.*

PRINCIPAL DISPLAY PANEL - 4 Autoinjectors Carton - NDC 72606-045-06 - avtozma 41

This is a product description for a single-dose autoinjector intended for subcutaneous use. The product contains etanercept as an active ingredient. It is manufactured by CELLTRION and distributed by CELLTRION USA. The package does not contain preservatives. The autoinjector is filled with 162 mg/0.9 ml solution. It is essential to dispense the enclosed Medication Guide to each patient.*

PRINCIPAL DISPLAY PANEL - 12 Autoinjectors Carton - NDC 72606-045-06 - avtozma 42

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.

Table of Contents